(PDF) Phosphodiesterase Type-5 Inhibitor Use in Type 2

Phosphodiesterase Type-5 Inhibitor Use in Type 2 Diabetes Is Associated With a Reduction in All Cause Mortality

Artery Research

doi 10.1016/j.artres.2014.09.162

Full Text

Abstract

Available in full text

Date

January 1, 2014

Authors

Publisher

Atlantis Press

Related search

Phosphodiesterase Type-5 Inhibitor Use in Type 2 Diabetes Is Associated With a Reduction in All-Cause Mortality

Cardiovascular Medicine

English

Diabetic Ketosis During Hyperglycemic Crisis Is Associated With Decreased All-Cause Mortality in Patients With Type 2 Diabetes Mellitus

English

Erythropoietin (EPO) Haplotype Associated With All-Cause Mortality in a Cohort of Italian Patients With Type-2 Diabetes

Scientific Reports

Multidisciplinary

English

Statin Use Reduces Cardiovascular Events and All-Cause Mortality Amongst Chinese Patients With Type 2 Diabetes Mellitus: A 5-Year Cohort Study

BMC Cardiovascular Disorders

Cardiovascular Medicine

English

More Work Is Needed to Better Understand Diabetes Distress as a Predictor of All-Cause Mortality in Type 2 Diabetes

Internal Medicine

English

Target Values of Cardiovascular Risk Factors Are Not Associated With All-Cause Mortality in Patients With Type 2 Diabetes Mellitus

Multidisciplinary

English

All-Cause Mortality and Estimated Renal Function in Type 2 Diabetes Mellitus Outpatients: Is There a Relationship With the Equation Used?

Diabetes and Vascular Disease Research

Internal Medicine

Cardiovascular Medicine

English

Television Viewing and Risk of Type 2 Diabetes, Cardiovascular Disease, and All-Cause Mortality

JAMA - Journal of the American Medical Association

English

The Relationship Between Estimated Glomerular Filtration Rate Trajectory and All-Cause Mortality in Type 2 Diabetes: The Fremantle Diabetes Study

European Journal of Endocrinology

English